Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

1.

Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington's disease.

Sugaya K, Matsubara S.

Mol Neurodegener. 2012 May 14;7:20. doi: 10.1186/1750-1326-7-20.

PMID:
22583646
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.

Sugaya K, Matsubara S, Kagamihara Y, Kawata A, Hayashi H.

PLoS One. 2007 Jul 25;2(7):e635.

PMID:
17653262
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.

Sugaya K.

Subcell Biochem. 2012;65:353-88. doi: 10.1007/978-94-007-5416-4_15. Review.

PMID:
23225011
[PubMed - indexed for MEDLINE]
4.

Nucleation of protein aggregation kinetics as a basis for genotype-phenotype correlations in polyglutamine diseases.

Sugaya K, Matsubara S.

Mol Neurodegener. 2009 Jul 15;4:29. doi: 10.1186/1750-1326-4-29.

PMID:
19602294
[PubMed]
Free PMC Article
5.

Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.

Chen S, Ferrone FA, Wetzel R.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11884-9. Epub 2002 Aug 19.

PMID:
12186976
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, Kazantsev AG.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):892-7. Epub 2005 Jan 10.

PMID:
15642944
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins.

Slepko N, Bhattacharyya AM, Jackson GR, Steffan JS, Marsh JL, Thompson LM, Wetzel R.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14367-72. Epub 2006 Sep 15.

PMID:
16980414
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Death of neuronal clusters contributes to variance of age at onset in Huntington's disease.

Cajavec B, Herzel H, Bernard S.

Neurogenetics. 2006 Mar;7(1):21-5. Epub 2006 Jan 14.

PMID:
16416264
[PubMed - indexed for MEDLINE]
9.

Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.

Wanker EE.

Biol Chem. 2000 Sep-Oct;381(9-10):937-42. Review.

PMID:
11076024
[PubMed - indexed for MEDLINE]
10.

Aggregation in Huntington's disease: insights through modelling.

Cajavec B, Bernard S, Herzel H.

Genome Inform. 2005;16(1):262-71.

PMID:
16362929
[PubMed - indexed for MEDLINE]
11.

Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Tower C, Fu L, Gill R, Prichard M, Lesort M, Sztul E.

Neurobiol Dis. 2011 Jan;41(1):11-22. doi: 10.1016/j.nbd.2010.08.013. Epub 2010 Aug 20.

PMID:
20732421
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Protein aggregation and neurodegeneration: clues from a yeast model of Huntington's disease.

Bocharova N, Chave-Cox R, Sokolov S, Knorre D, Severin F.

Biochemistry (Mosc). 2009 Feb;74(2):231-4.

PMID:
19267681
[PubMed - indexed for MEDLINE]
Free Article
13.

Biophysical underpinnings of the repeat length dependence of polyglutamine amyloid formation.

Landrum E, Wetzel R.

J Biol Chem. 2014 Apr 11;289(15):10254-60. doi: 10.1074/jbc.C114.552943. Epub 2014 Mar 4.

PMID:
24596088
[PubMed - indexed for MEDLINE]
14.

A huntingtin peptide inhibits polyQ-huntingtin associated defects.

Arribat Y, Bonneaud N, Talmat-Amar Y, Layalle S, Parmentier ML, Maschat F.

PLoS One. 2013 Jul 4;8(7):e68775. doi: 10.1371/journal.pone.0068775. Print 2013.

PMID:
23861941
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity.

Chen S, Berthelier V, Yang W, Wetzel R.

J Mol Biol. 2001 Aug 3;311(1):173-82.

PMID:
11469866
[PubMed - indexed for MEDLINE]
16.

Towards the treatment of polyglutamine diseases: the modulatory role of protein context.

Robertson AL, Bottomley SP.

Curr Med Chem. 2010;17(27):3058-68. Review.

PMID:
20629626
[PubMed - indexed for MEDLINE]
17.

Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.

Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP.

Neurobiol Dis. 2001 Dec;8(6):1017-26.

PMID:
11741397
[PubMed - indexed for MEDLINE]
18.

Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death.

Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13318-23. Epub 2001 Oct 30.

PMID:
11687635
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent.

Kar K, Jayaraman M, Sahoo B, Kodali R, Wetzel R.

Nat Struct Mol Biol. 2011 Mar;18(3):328-36. doi: 10.1038/nsmb.1992. Epub 2011 Feb 13.

PMID:
21317897
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins.

Krobitsch S, Lindquist S.

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1589-94.

PMID:
10677504
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk